Home > Insider Trading > Filing (0001209191-17-044940)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1377121	Protagonist Therapeutics Inc	PTGX	Pharmaceutical Preparations (2834)	980505495

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1675881	Y David Liu	C/O Protagonist Therapeutics, Inc. 7707 Gateway Blvd., Suite 140 Newark CA 94560-1160	Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-07-10	3,500	$1.89	5,500	No	4	M	Direct
Common Stock	Disposition	2017-07-10	3,500	$12.68	2,000	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2017-07-10	3,500	$0.00	3,500	$1.89

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
16,725		2024-10-22	No	4	M	Direct

Footnotes

Includes 2,000 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2017.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2017.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.36 to $12.84. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The option vests over a four-year period, with 1/4th of the shares subject to the option vesting on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option vesting each month, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date.